| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Herpes Zoster | 8 | 2024 | 82 | 2.980 |
Why?
|
| Prostatic Neoplasms | 11 | 2022 | 263 | 2.290 |
Why?
|
| Uterine Cervical Neoplasms | 14 | 2022 | 131 | 2.090 |
Why?
|
| Breast Neoplasms | 19 | 2025 | 969 | 1.800 |
Why?
|
| Chickenpox Vaccine | 8 | 2020 | 91 | 1.690 |
Why?
|
| Chickenpox | 4 | 2020 | 35 | 1.510 |
Why?
|
| Humans | 99 | 2025 | 17314 | 1.360 |
Why?
|
| Vaccination | 7 | 2020 | 688 | 1.140 |
Why?
|
| Neoplasm Recurrence, Local | 6 | 2025 | 243 | 1.070 |
Why?
|
| Female | 74 | 2025 | 12396 | 1.030 |
Why?
|
| Middle Aged | 55 | 2025 | 7836 | 1.020 |
Why?
|
| Herpesvirus 3, Human | 4 | 2024 | 44 | 0.980 |
Why?
|
| Case-Control Studies | 29 | 2025 | 1098 | 0.920 |
Why?
|
| Male | 54 | 2025 | 9804 | 0.910 |
Why?
|
| Prostatectomy | 6 | 2019 | 75 | 0.900 |
Why?
|
| Mass Screening | 10 | 2017 | 672 | 0.890 |
Why?
|
| Risk Factors | 37 | 2025 | 3258 | 0.870 |
Why?
|
| Aged | 48 | 2025 | 6084 | 0.860 |
Why?
|
| Biomarkers, Tumor | 6 | 2020 | 145 | 0.830 |
Why?
|
| United States | 30 | 2025 | 3866 | 0.820 |
Why?
|
| Cervical Intraepithelial Neoplasia | 5 | 2017 | 16 | 0.820 |
Why?
|
| Air Pollutants, Occupational | 2 | 2016 | 16 | 0.810 |
Why?
|
| Occupational Exposure | 2 | 2016 | 67 | 0.780 |
Why?
|
| Prostate | 5 | 2022 | 28 | 0.770 |
Why?
|
| Retrospective Studies | 23 | 2025 | 2415 | 0.760 |
Why?
|
| Heart Arrest | 13 | 2005 | 33 | 0.760 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 3 | 2016 | 195 | 0.740 |
Why?
|
| Child | 20 | 2025 | 2403 | 0.730 |
Why?
|
| Dementia | 1 | 2024 | 121 | 0.730 |
Why?
|
| Papillomavirus Infections | 7 | 2020 | 142 | 0.720 |
Why?
|
| Papillomavirus Vaccines | 6 | 2020 | 114 | 0.720 |
Why?
|
| Diagnostic Imaging | 4 | 2025 | 42 | 0.710 |
Why?
|
| Infant | 11 | 2025 | 1161 | 0.700 |
Why?
|
| Adult | 44 | 2025 | 7500 | 0.700 |
Why?
|
| Child, Preschool | 13 | 2025 | 1380 | 0.680 |
Why?
|
| Incidence | 11 | 2024 | 1266 | 0.670 |
Why?
|
| Cancer Survivors | 4 | 2023 | 101 | 0.670 |
Why?
|
| Mumps | 1 | 2020 | 12 | 0.660 |
Why?
|
| Measles | 1 | 2020 | 24 | 0.640 |
Why?
|
| Early Detection of Cancer | 10 | 2022 | 529 | 0.600 |
Why?
|
| Smoking | 7 | 2015 | 429 | 0.570 |
Why?
|
| Young Adult | 20 | 2025 | 2465 | 0.570 |
Why?
|
| Tobacco Smoke Pollution | 2 | 2015 | 33 | 0.560 |
Why?
|
| Radiation Dosage | 4 | 2025 | 14 | 0.560 |
Why?
|
| Adolescent | 19 | 2025 | 3538 | 0.560 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 3 | 2025 | 42 | 0.510 |
Why?
|
| Risk Assessment | 14 | 2025 | 1076 | 0.510 |
Why?
|
| Family Characteristics | 1 | 2016 | 57 | 0.490 |
Why?
|
| Pregnancy Outcome | 1 | 2017 | 158 | 0.480 |
Why?
|
| Oregon | 6 | 2016 | 170 | 0.460 |
Why?
|
| Urinary Bladder Neoplasms | 3 | 2019 | 57 | 0.450 |
Why?
|
| Radiation Exposure | 2 | 2025 | 5 | 0.450 |
Why?
|
| Tomography, X-Ray Computed | 7 | 2023 | 203 | 0.450 |
Why?
|
| Trans-Activators | 2 | 2018 | 9 | 0.450 |
Why?
|
| Health Maintenance Organizations | 6 | 2012 | 407 | 0.440 |
Why?
|
| Whooping Cough | 1 | 2015 | 65 | 0.430 |
Why?
|
| Cohort Studies | 13 | 2024 | 2514 | 0.410 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2013 | 3 | 0.410 |
Why?
|
| Infant, Newborn | 5 | 2019 | 805 | 0.410 |
Why?
|
| Breast Diseases | 2 | 2025 | 18 | 0.400 |
Why?
|
| Aged, 80 and over | 13 | 2025 | 1925 | 0.400 |
Why?
|
| Neoplasms, Second Primary | 2 | 2023 | 31 | 0.390 |
Why?
|
| Obesity | 2 | 2017 | 814 | 0.360 |
Why?
|
| Papillomaviridae | 6 | 2020 | 61 | 0.360 |
Why?
|
| Logistic Models | 11 | 2015 | 879 | 0.350 |
Why?
|
| Receptors, Androgen | 2 | 2022 | 9 | 0.350 |
Why?
|
| Neoplasms, Radiation-Induced | 2 | 2025 | 5 | 0.350 |
Why?
|
| Skin Neoplasms | 1 | 2011 | 58 | 0.330 |
Why?
|
| Papanicolaou Test | 6 | 2017 | 37 | 0.330 |
Why?
|
| Body Mass Index | 2 | 2014 | 937 | 0.320 |
Why?
|
| Prostate-Specific Antigen | 3 | 2019 | 75 | 0.320 |
Why?
|
| Behavior Therapy | 1 | 2011 | 126 | 0.320 |
Why?
|
| Counseling | 1 | 2011 | 174 | 0.310 |
Why?
|
| Mammography | 3 | 2005 | 168 | 0.310 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 2 | 2019 | 3 | 0.300 |
Why?
|
| Follow-Up Studies | 8 | 2025 | 1151 | 0.300 |
Why?
|
| Adenocarcinoma | 2 | 2013 | 173 | 0.300 |
Why?
|
| Health Behavior | 1 | 2011 | 346 | 0.290 |
Why?
|
| Colonoscopy | 3 | 2015 | 257 | 0.280 |
Why?
|
| 5-alpha Reductase Inhibitors | 2 | 2018 | 7 | 0.280 |
Why?
|
| Prognosis | 8 | 2025 | 603 | 0.280 |
Why?
|
| Condylomata Acuminata | 2 | 2020 | 23 | 0.270 |
Why?
|
| Prostatic Hyperplasia | 2 | 2018 | 24 | 0.270 |
Why?
|
| Breast | 2 | 2025 | 84 | 0.270 |
Why?
|
| Delivery of Health Care | 4 | 2020 | 390 | 0.260 |
Why?
|
| Neoplasms | 3 | 2022 | 446 | 0.260 |
Why?
|
| Antibodies, Viral | 3 | 2020 | 66 | 0.250 |
Why?
|
| Colorectal Neoplasms | 3 | 2020 | 622 | 0.250 |
Why?
|
| Hematologic Neoplasms | 1 | 2025 | 9 | 0.240 |
Why?
|
| Odds Ratio | 9 | 2021 | 640 | 0.240 |
Why?
|
| Palpation | 1 | 2005 | 10 | 0.240 |
Why?
|
| Cellular Senescence | 1 | 2025 | 2 | 0.230 |
Why?
|
| Databases, Factual | 3 | 2016 | 304 | 0.230 |
Why?
|
| Primary Health Care | 1 | 2011 | 726 | 0.230 |
Why?
|
| Tamoxifen | 2 | 2022 | 55 | 0.230 |
Why?
|
| Treatment Refusal | 1 | 2005 | 30 | 0.230 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2022 | 51 | 0.230 |
Why?
|
| Pregnancy | 6 | 2022 | 1463 | 0.230 |
Why?
|
| Surveys and Questionnaires | 3 | 2019 | 1282 | 0.220 |
Why?
|
| Washington | 8 | 2013 | 384 | 0.210 |
Why?
|
| Down Syndrome | 1 | 2023 | 4 | 0.210 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2023 | 2 | 0.210 |
Why?
|
| Transcriptome | 2 | 2021 | 25 | 0.200 |
Why?
|
| Dust | 2 | 2016 | 22 | 0.200 |
Why?
|
| Reproducibility of Results | 4 | 2019 | 357 | 0.200 |
Why?
|
| Hemangiosarcoma | 1 | 2022 | 1 | 0.200 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2022 | 1 | 0.200 |
Why?
|
| Sarcoma | 1 | 2022 | 2 | 0.200 |
Why?
|
| Nomograms | 2 | 2025 | 12 | 0.190 |
Why?
|
| Leukemia | 1 | 2022 | 9 | 0.190 |
Why?
|
| Biological Specimen Banks | 1 | 2022 | 11 | 0.190 |
Why?
|
| Neoplasm Grading | 4 | 2017 | 49 | 0.190 |
Why?
|
| Ontario | 4 | 2025 | 19 | 0.190 |
Why?
|
| Neoplasm Metastasis | 2 | 2019 | 31 | 0.190 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2013 | 56 | 0.180 |
Why?
|
| Adrenergic alpha-Antagonists | 2 | 2018 | 9 | 0.180 |
Why?
|
| Postpartum Period | 1 | 2021 | 79 | 0.170 |
Why?
|
| Neoplastic Stem Cells | 1 | 2020 | 1 | 0.170 |
Why?
|
| Hypertension | 3 | 2022 | 469 | 0.170 |
Why?
|
| Unnecessary Procedures | 1 | 2020 | 21 | 0.170 |
Why?
|
| Bariatric Surgery | 2 | 2020 | 129 | 0.170 |
Why?
|
| Pulmonary Embolism | 1 | 2020 | 44 | 0.170 |
Why?
|
| Algorithms | 4 | 2015 | 223 | 0.170 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2019 | 102 | 0.170 |
Why?
|
| Microfilament Proteins | 1 | 2020 | 3 | 0.170 |
Why?
|
| Calcium-Binding Proteins | 1 | 2020 | 3 | 0.170 |
Why?
|
| Epithelial Cells | 1 | 2020 | 5 | 0.160 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2020 | 5 | 0.160 |
Why?
|
| Quality Improvement | 1 | 2022 | 188 | 0.160 |
Why?
|
| Paraffin Embedding | 1 | 2019 | 5 | 0.160 |
Why?
|
| Tissue Fixation | 1 | 2019 | 3 | 0.160 |
Why?
|
| Formaldehyde | 1 | 2019 | 5 | 0.160 |
Why?
|
| Vaccines, Combined | 1 | 2020 | 80 | 0.160 |
Why?
|
| Cystectomy | 1 | 2019 | 7 | 0.160 |
Why?
|
| Measles-Mumps-Rubella Vaccine | 1 | 2020 | 62 | 0.160 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2020 | 52 | 0.160 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2019 | 123 | 0.160 |
Why?
|
| Neoplasm Staging | 6 | 2020 | 338 | 0.160 |
Why?
|
| Immunity, Herd | 1 | 2019 | 4 | 0.160 |
Why?
|
| Registries | 3 | 2022 | 460 | 0.160 |
Why?
|
| Mass Vaccination | 1 | 2019 | 22 | 0.160 |
Why?
|
| Public Health | 1 | 2019 | 83 | 0.150 |
Why?
|
| MicroRNAs | 1 | 2019 | 17 | 0.150 |
Why?
|
| Gene Expression Profiling | 1 | 2019 | 35 | 0.150 |
Why?
|
| Proportional Hazards Models | 2 | 2022 | 701 | 0.150 |
Why?
|
| HIV Seroprevalence | 1 | 1998 | 2 | 0.150 |
Why?
|
| Sensitivity and Specificity | 2 | 2016 | 298 | 0.150 |
Why?
|
| Histone Demethylases | 1 | 2018 | 3 | 0.140 |
Why?
|
| Gene Regulatory Networks | 1 | 2018 | 9 | 0.140 |
Why?
|
| Neoplasm Proteins | 1 | 2018 | 10 | 0.140 |
Why?
|
| International Classification of Diseases | 2 | 2016 | 86 | 0.140 |
Why?
|
| Viral Vaccines | 1 | 2018 | 12 | 0.140 |
Why?
|
| Pericarditis | 1 | 2018 | 11 | 0.140 |
Why?
|
| Alphapapillomavirus | 2 | 2020 | 13 | 0.140 |
Why?
|
| Vaccines, Attenuated | 1 | 2018 | 45 | 0.140 |
Why?
|
| Myocarditis | 1 | 2018 | 14 | 0.140 |
Why?
|
| Demography | 2 | 2017 | 93 | 0.140 |
Why?
|
| Caffeine | 1 | 1997 | 18 | 0.140 |
Why?
|
| Receptor, ErbB-2 | 2 | 2022 | 47 | 0.140 |
Why?
|
| Live Birth | 1 | 2017 | 8 | 0.130 |
Why?
|
| Receptors, Estrogen | 3 | 2022 | 53 | 0.130 |
Why?
|
| Behavior | 1 | 2017 | 17 | 0.130 |
Why?
|
| Infant, Low Birth Weight | 1 | 2017 | 29 | 0.130 |
Why?
|
| National Institute for Occupational Safety and Health (U.S.) | 1 | 2016 | 1 | 0.130 |
Why?
|
| Gases | 1 | 2016 | 2 | 0.130 |
Why?
|
| Inhalation Exposure | 1 | 2016 | 5 | 0.130 |
Why?
|
| Occupations | 1 | 2016 | 15 | 0.130 |
Why?
|
| Cesarean Section | 1 | 2017 | 33 | 0.130 |
Why?
|
| Quality of Life | 1 | 2019 | 499 | 0.120 |
Why?
|
| Medical Record Linkage | 1 | 2016 | 36 | 0.120 |
Why?
|
| Polymerase Chain Reaction | 3 | 2015 | 52 | 0.120 |
Why?
|
| Multivariate Analysis | 2 | 2017 | 535 | 0.120 |
Why?
|
| Electronic Health Records | 3 | 2022 | 704 | 0.120 |
Why?
|
| Salvage Therapy | 1 | 2015 | 17 | 0.120 |
Why?
|
| Treatment Failure | 1 | 2015 | 31 | 0.120 |
Why?
|
| DNA, Viral | 3 | 2014 | 18 | 0.120 |
Why?
|
| Radiometry | 1 | 2015 | 2 | 0.120 |
Why?
|
| Age Factors | 6 | 2015 | 878 | 0.120 |
Why?
|
| ROC Curve | 1 | 2015 | 72 | 0.120 |
Why?
|
| Genomics | 1 | 2015 | 56 | 0.120 |
Why?
|
| Premature Birth | 1 | 2017 | 132 | 0.120 |
Why?
|
| Weight Loss | 1 | 2017 | 294 | 0.120 |
Why?
|
| Pregnancy Rate | 1 | 2015 | 6 | 0.120 |
Why?
|
| Decision Making | 2 | 2019 | 171 | 0.120 |
Why?
|
| Community Health Centers | 1 | 2015 | 64 | 0.120 |
Why?
|
| Pertussis Vaccine | 1 | 2015 | 14 | 0.110 |
Why?
|
| Carcinoma, Renal Cell | 1 | 1994 | 10 | 0.110 |
Why?
|
| Diuretics | 1 | 1994 | 19 | 0.110 |
Why?
|
| Kidney Neoplasms | 1 | 1994 | 15 | 0.110 |
Why?
|
| Precancerous Conditions | 1 | 2015 | 48 | 0.110 |
Why?
|
| Pneumococcal Infections | 1 | 2014 | 44 | 0.110 |
Why?
|
| Vaginal Smears | 3 | 2013 | 47 | 0.110 |
Why?
|
| Mastectomy, Segmental | 2 | 2025 | 21 | 0.110 |
Why?
|
| Predictive Value of Tests | 2 | 2013 | 342 | 0.110 |
Why?
|
| Medical Records | 4 | 2012 | 91 | 0.110 |
Why?
|
| Colonic Neoplasms | 1 | 2015 | 163 | 0.100 |
Why?
|
| Interviews as Topic | 2 | 2019 | 306 | 0.100 |
Why?
|
| Immunocompromised Host | 1 | 2013 | 18 | 0.100 |
Why?
|
| Transcriptional Regulator ERG | 1 | 2013 | 3 | 0.100 |
Why?
|
| Cytodiagnosis | 1 | 2013 | 3 | 0.100 |
Why?
|
| Immunohistochemistry | 1 | 2013 | 45 | 0.100 |
Why?
|
| Antihypertensive Agents | 1 | 1994 | 154 | 0.100 |
Why?
|
| Carcinoma in Situ | 1 | 2013 | 17 | 0.100 |
Why?
|
| Radiography | 2 | 2023 | 36 | 0.100 |
Why?
|
| Immunoglobulin M | 2 | 2011 | 8 | 0.090 |
Why?
|
| Immunoglobulin G | 2 | 2011 | 29 | 0.090 |
Why?
|
| Practice Guidelines as Topic | 2 | 2003 | 310 | 0.090 |
Why?
|
| Biopsy | 2 | 2025 | 82 | 0.090 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2011 | 93 | 0.090 |
Why?
|
| Suntan | 1 | 2011 | 2 | 0.090 |
Why?
|
| Ultraviolet Rays | 1 | 2011 | 6 | 0.090 |
Why?
|
| Sunscreening Agents | 1 | 2011 | 5 | 0.090 |
Why?
|
| Prevalence | 4 | 2019 | 840 | 0.090 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2011 | 29 | 0.090 |
Why?
|
| Sunlight | 1 | 2011 | 13 | 0.090 |
Why?
|
| Herpes Zoster Vaccine | 1 | 2011 | 59 | 0.090 |
Why?
|
| Genetic Testing | 1 | 2011 | 69 | 0.090 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2011 | 24 | 0.090 |
Why?
|
| Melanoma | 1 | 2011 | 35 | 0.080 |
Why?
|
| Early Diagnosis | 3 | 2005 | 36 | 0.080 |
Why?
|
| Delivery of Health Care, Integrated | 2 | 2013 | 535 | 0.080 |
Why?
|
| Time Factors | 4 | 2020 | 1039 | 0.080 |
Why?
|
| Urinary Bladder | 2 | 2019 | 10 | 0.080 |
Why?
|
| Body Size | 1 | 2009 | 31 | 0.080 |
Why?
|
| Neoplasm Invasiveness | 2 | 2011 | 79 | 0.080 |
Why?
|
| Respiratory Protective Devices | 1 | 2008 | 3 | 0.070 |
Why?
|
| Convalescence | 1 | 2008 | 2 | 0.070 |
Why?
|
| Spirometry | 1 | 2008 | 66 | 0.070 |
Why?
|
| Fatty Acids, Omega-3 | 2 | 2000 | 21 | 0.070 |
Why?
|
| Acute Disease | 1 | 2008 | 144 | 0.070 |
Why?
|
| Genotype | 2 | 2019 | 223 | 0.070 |
Why?
|
| Northwestern United States | 2 | 2020 | 53 | 0.070 |
Why?
|
| Ethnic Groups | 2 | 2019 | 451 | 0.070 |
Why?
|
| Confidence Intervals | 3 | 2005 | 231 | 0.060 |
Why?
|
| Bone Marrow | 1 | 2025 | 2 | 0.060 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2025 | 4 | 0.060 |
Why?
|
| European Continental Ancestry Group | 1 | 2008 | 476 | 0.060 |
Why?
|
| Long QT Syndrome | 1 | 2005 | 5 | 0.060 |
Why?
|
| Diabetic Angiopathies | 1 | 2005 | 31 | 0.060 |
Why?
|
| Rectum | 1 | 2005 | 13 | 0.060 |
Why?
|
| African Americans | 1 | 2008 | 439 | 0.060 |
Why?
|
| Death, Sudden, Cardiac | 2 | 2002 | 32 | 0.060 |
Why?
|
| Sex Factors | 2 | 2015 | 603 | 0.060 |
Why?
|
| Random Allocation | 1 | 2004 | 33 | 0.050 |
Why?
|
| Physical Examination | 1 | 2004 | 19 | 0.050 |
Why?
|
| Organizational Case Studies | 1 | 2003 | 21 | 0.050 |
Why?
|
| Organizational Policy | 1 | 2003 | 12 | 0.050 |
Why?
|
| Genetic Counseling | 1 | 2003 | 27 | 0.050 |
Why?
|
| Leadership | 1 | 2003 | 35 | 0.050 |
Why?
|
| Cardiotonic Agents | 1 | 2003 | 12 | 0.050 |
Why?
|
| Digoxin | 1 | 2003 | 12 | 0.050 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2003 | 53 | 0.050 |
Why?
|
| Population Surveillance | 2 | 2011 | 252 | 0.050 |
Why?
|
| Kidney | 1 | 2003 | 52 | 0.050 |
Why?
|
| Ovarian Neoplasms | 1 | 2003 | 52 | 0.050 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2002 | 33 | 0.050 |
Why?
|
| Myocardial Infarction | 2 | 2002 | 224 | 0.050 |
Why?
|
| Health Services Accessibility | 1 | 2005 | 271 | 0.050 |
Why?
|
| Mastectomy | 1 | 2022 | 35 | 0.050 |
Why?
|
| Self Care | 1 | 2003 | 144 | 0.050 |
Why?
|
| Genes, myc | 1 | 2022 | 3 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2022 | 5 | 0.050 |
Why?
|
| Ki-67 Antigen | 1 | 2022 | 2 | 0.050 |
Why?
|
| Cell Line, Tumor | 1 | 2022 | 12 | 0.050 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2022 | 4 | 0.050 |
Why?
|
| Human papillomavirus 18 | 1 | 2022 | 3 | 0.050 |
Why?
|
| Referral and Consultation | 1 | 2003 | 157 | 0.050 |
Why?
|
| Human papillomavirus 16 | 1 | 2022 | 7 | 0.050 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2002 | 5 | 0.050 |
Why?
|
| Cell Membrane | 1 | 2002 | 6 | 0.050 |
Why?
|
| Receptors, Progesterone | 1 | 2022 | 50 | 0.050 |
Why?
|
| Breast Density | 1 | 2022 | 31 | 0.050 |
Why?
|
| Hypertrophy | 1 | 2021 | 1 | 0.050 |
Why?
|
| Tumor Microenvironment | 1 | 2021 | 4 | 0.050 |
Why?
|
| Genes, p53 | 1 | 2021 | 7 | 0.050 |
Why?
|
| Cell Cycle | 1 | 2021 | 4 | 0.050 |
Why?
|
| Cell Proliferation | 1 | 2021 | 19 | 0.050 |
Why?
|
| Immunity | 1 | 2021 | 6 | 0.050 |
Why?
|
| Aromatase Inhibitors | 1 | 2022 | 33 | 0.050 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2021 | 20 | 0.050 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2022 | 65 | 0.050 |
Why?
|
| Mutation | 1 | 2021 | 132 | 0.040 |
Why?
|
| Diabetes Mellitus | 1 | 2005 | 452 | 0.040 |
Why?
|
| Disease Susceptibility | 1 | 2021 | 37 | 0.040 |
Why?
|
| Computed Tomography Angiography | 1 | 2020 | 3 | 0.040 |
Why?
|
| Public Health Surveillance | 1 | 2021 | 43 | 0.040 |
Why?
|
| Cell Adhesion Molecules, Neuronal | 1 | 2020 | 1 | 0.040 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2020 | 2 | 0.040 |
Why?
|
| Hyaluronan Receptors | 1 | 2020 | 4 | 0.040 |
Why?
|
| Fetal Proteins | 1 | 2020 | 4 | 0.040 |
Why?
|
| Antigens, CD | 1 | 2020 | 7 | 0.040 |
Why?
|
| Indians, North American | 1 | 2000 | 48 | 0.040 |
Why?
|
| Insurance, Health | 1 | 2022 | 170 | 0.040 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2020 | 3 | 0.040 |
Why?
|
| Premenopause | 1 | 2020 | 24 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2000 | 120 | 0.040 |
Why?
|
| Erythrocyte Membrane | 2 | 2000 | 4 | 0.040 |
Why?
|
| Signal Transduction | 1 | 2019 | 34 | 0.040 |
Why?
|
| Genetic Heterogeneity | 1 | 2019 | 3 | 0.040 |
Why?
|
| Radionuclide Imaging | 1 | 2019 | 4 | 0.040 |
Why?
|
| Risk | 2 | 2017 | 496 | 0.040 |
Why?
|
| Thorax | 1 | 2019 | 5 | 0.040 |
Why?
|
| Spine | 1 | 2019 | 8 | 0.040 |
Why?
|
| Urologists | 1 | 2019 | 2 | 0.040 |
Why?
|
| Head | 1 | 2019 | 6 | 0.040 |
Why?
|
| Abdomen | 1 | 2019 | 20 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2022 | 674 | 0.040 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2019 | 46 | 0.040 |
Why?
|
| Radiation, Ionizing | 1 | 2019 | 3 | 0.040 |
Why?
|
| Ultrasonography | 1 | 2019 | 33 | 0.040 |
Why?
|
| Cytological Techniques | 1 | 2019 | 2 | 0.040 |
Why?
|
| Patient Selection | 1 | 2000 | 176 | 0.040 |
Why?
|
| Asthma | 1 | 2002 | 400 | 0.040 |
Why?
|
| Sequence Analysis, RNA | 1 | 2019 | 1 | 0.040 |
Why?
|
| Immunization Schedule | 1 | 2020 | 124 | 0.040 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2019 | 10 | 0.040 |
Why?
|
| Minority Groups | 1 | 2019 | 104 | 0.040 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2019 | 9 | 0.040 |
Why?
|
| Gestational Age | 1 | 2019 | 112 | 0.040 |
Why?
|
| Leisure Activities | 1 | 1999 | 34 | 0.040 |
Why?
|
| Europe | 1 | 2019 | 46 | 0.040 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2005 | 664 | 0.040 |
Why?
|
| Postmenopause | 1 | 2020 | 248 | 0.040 |
Why?
|
| Disease Progression | 1 | 2019 | 259 | 0.040 |
Why?
|
| Emergency Medical Technicians | 1 | 1998 | 1 | 0.040 |
Why?
|
| HIV-2 | 1 | 1998 | 1 | 0.040 |
Why?
|
| Blotting, Western | 1 | 1998 | 2 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1998 | 14 | 0.040 |
Why?
|
| Occupational Diseases | 1 | 1998 | 38 | 0.040 |
Why?
|
| Emergency Medical Services | 1 | 1998 | 48 | 0.040 |
Why?
|
| Hydrazines | 1 | 2018 | 2 | 0.040 |
Why?
|
| HIV-1 | 1 | 1998 | 71 | 0.040 |
Why?
|
| Cell Survival | 1 | 2018 | 11 | 0.040 |
Why?
|
| Sulfonamides | 1 | 2018 | 15 | 0.040 |
Why?
|
| Cross-Sectional Studies | 1 | 2022 | 1280 | 0.040 |
Why?
|
| Prenatal Care | 1 | 2019 | 127 | 0.040 |
Why?
|
| Heart Failure | 1 | 2003 | 401 | 0.030 |
Why?
|
| Insurance Claim Review | 1 | 2017 | 49 | 0.030 |
Why?
|
| Diet Surveys | 1 | 1997 | 56 | 0.030 |
Why?
|
| Cause of Death | 1 | 2018 | 176 | 0.030 |
Why?
|
| Electrocoagulation | 1 | 2017 | 3 | 0.030 |
Why?
|
| Netherlands | 1 | 2017 | 6 | 0.030 |
Why?
|
| Obstetric Labor, Premature | 1 | 2017 | 8 | 0.030 |
Why?
|
| California | 2 | 2014 | 2311 | 0.030 |
Why?
|
| Influenza Vaccines | 1 | 2000 | 292 | 0.030 |
Why?
|
| Thyroid Hormones | 1 | 1996 | 7 | 0.030 |
Why?
|
| Hemorrhage | 1 | 2017 | 62 | 0.030 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2019 | 302 | 0.030 |
Why?
|
| Socioeconomic Factors | 2 | 2014 | 605 | 0.030 |
Why?
|
| Pain | 1 | 2017 | 75 | 0.030 |
Why?
|
| Phantoms, Imaging | 1 | 2015 | 5 | 0.030 |
Why?
|
| Monte Carlo Method | 1 | 2015 | 12 | 0.030 |
Why?
|
| Anxiety | 1 | 2017 | 154 | 0.030 |
Why?
|
| Automation | 1 | 2015 | 25 | 0.030 |
Why?
|
| Genotyping Techniques | 1 | 2015 | 26 | 0.030 |
Why?
|
| Streptococcus pneumoniae | 1 | 2014 | 21 | 0.030 |
Why?
|
| Epidemiologic Methods | 1 | 1994 | 72 | 0.030 |
Why?
|
| Sentinel Surveillance | 1 | 2014 | 12 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2014 | 40 | 0.030 |
Why?
|
| Exercise | 1 | 1999 | 515 | 0.030 |
Why?
|
| Diet | 1 | 1995 | 355 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2016 | 1160 | 0.030 |
Why?
|
| Sigmoidoscopy | 1 | 2013 | 65 | 0.020 |
Why?
|
| HIV Infections | 1 | 1998 | 712 | 0.020 |
Why?
|
| Nervous System Diseases | 1 | 2011 | 19 | 0.020 |
Why?
|
| Hypersensitivity | 1 | 2011 | 22 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2011 | 22 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2011 | 15 | 0.020 |
Why?
|
| Trastuzumab | 1 | 2011 | 19 | 0.020 |
Why?
|
| SEER Program | 1 | 2011 | 92 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2011 | 58 | 0.020 |
Why?
|
| Seafood | 2 | 2000 | 8 | 0.020 |
Why?
|
| Cardiovascular Diseases | 1 | 2011 | 532 | 0.020 |
Why?
|
| Electrocardiography | 1 | 2005 | 38 | 0.010 |
Why?
|
| Reference Values | 1 | 2005 | 87 | 0.010 |
Why?
|
| False Negative Reactions | 1 | 2005 | 12 | 0.010 |
Why?
|
| Decision Trees | 1 | 2005 | 18 | 0.010 |
Why?
|
| Steroids | 1 | 2005 | 12 | 0.010 |
Why?
|
| Epidemiologic Studies | 1 | 2005 | 29 | 0.010 |
Why?
|
| Poverty Areas | 1 | 2005 | 21 | 0.010 |
Why?
|
| Confounding Factors (Epidemiology) | 1 | 2005 | 84 | 0.010 |
Why?
|
| Marital Status | 1 | 2004 | 20 | 0.010 |
Why?
|
| Educational Status | 1 | 2004 | 177 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2005 | 118 | 0.010 |
Why?
|
| Creatinine | 1 | 2003 | 66 | 0.010 |
Why?
|
| Receptors, Adrenergic, beta-2 | 1 | 2002 | 2 | 0.010 |
Why?
|
| Administration, Inhalation | 1 | 2002 | 40 | 0.010 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2002 | 89 | 0.010 |
Why?
|
| Oleic Acid | 1 | 2002 | 1 | 0.010 |
Why?
|
| Linoleic Acid | 1 | 2002 | 1 | 0.010 |
Why?
|
| Dietary Fats, Unsaturated | 1 | 2002 | 4 | 0.010 |
Why?
|
| Stereoisomerism | 1 | 2002 | 2 | 0.010 |
Why?
|
| Molecular Conformation | 1 | 2002 | 2 | 0.010 |
Why?
|
| Erythrocytes | 1 | 2002 | 8 | 0.010 |
Why?
|
| Family Health | 1 | 2002 | 45 | 0.010 |
Why?
|
| Interpersonal Relations | 1 | 2002 | 41 | 0.010 |
Why?
|
| Sex Distribution | 1 | 2002 | 180 | 0.010 |
Why?
|
| Age Distribution | 1 | 2002 | 239 | 0.010 |
Why?
|
| Cultural Characteristics | 1 | 2000 | 4 | 0.010 |
Why?
|
| Alaska | 1 | 2000 | 16 | 0.010 |
Why?
|
| Communication Barriers | 1 | 2000 | 29 | 0.010 |
Why?
|
| Health Status Indicators | 1 | 2000 | 59 | 0.010 |
Why?
|
| Eating | 1 | 2000 | 34 | 0.010 |
Why?
|
| Attitude to Health | 1 | 2000 | 147 | 0.010 |
Why?
|
| Walking | 1 | 1999 | 89 | 0.010 |
Why?
|
| Life Style | 1 | 1999 | 316 | 0.010 |
Why?
|
| Influenza, Human | 1 | 2000 | 282 | 0.010 |
Why?
|
| Triiodothyronine, Reverse | 1 | 1996 | 1 | 0.010 |
Why?
|
| Triiodothyronine | 1 | 1996 | 4 | 0.010 |
Why?
|
| Thyroxine | 1 | 1996 | 7 | 0.010 |
Why?
|
| Thyrotropin | 1 | 1996 | 7 | 0.010 |
Why?
|
| Docosahexaenoic Acids | 1 | 1995 | 7 | 0.010 |
Why?
|
| Eicosapentaenoic Acid | 1 | 1995 | 9 | 0.010 |
Why?
|
| Nutrition Assessment | 1 | 1995 | 26 | 0.010 |
Why?
|
| Likelihood Functions | 1 | 1995 | 45 | 0.010 |
Why?
|
| Arrhythmias, Cardiac | 1 | 1995 | 31 | 0.010 |
Why?
|
| Biomarkers | 1 | 1995 | 307 | 0.010 |
Why?
|
| Research Design | 1 | 1995 | 336 | 0.010 |
Why?
|